SEC Form 4 · accession 0000899243-16-035014
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary M. Rozenman
Officer — See Remarks
Period of report
Nov 29, 2016
Accepted (ET)
Dec 6, 2016 · 8:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Nov 29, 2016 | J | 129 | $0.00 | A | 129 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Longitude Venture Partners II, L.P. distributed an aggregate of 1,500,000 shares of common stock of the issuer to its limited and general partners for no consideration on November 29, 2016. Reflects Reporting Person's pro rata allocation of such shares.
Remarks
Senior VP, Corporate Development & Strategy